Cynthia Demicheli Selected Research

Meglumine Antimoniate

6/2021	Use of liposomal nanoformulations in antileishmania therapy: challenges and perspectives.
1/2020	Therapeutic Efficacy of a Mixed Formulation of Conventional and PEGylated Liposomes Containing Meglumine Antimoniate, Combined with Allopurinol, in Dogs Naturally Infected with Leishmania infantum.
1/2018	Efficacy of Meglumine Antimoniate in a Low Polymerization State Orally Administered in a Murine Model of Visceral Leishmaniasis.
12/2015	Nanoparticle phosphate-based composites as vehicles for antimony delivery to macrophages: possible use in leishmaniasis.
10/2014	Mixed formulation of conventional and pegylated liposomes as a novel drug delivery strategy for improved treatment of visceral leishmaniasis.
1/2014	Hepatotoxicity of pentavalent antimonial drug: possible role of residual Sb(III) and protective effect of ascorbic acid.
9/2013	Amphiphilic Antimony(V) Complexes for Oral Treatment of Visceral Leishmaniasis.
6/2012	Efficacy of combined therapy with liposome-encapsulated meglumine antimoniate and allopurinol in treatment of canine visceral leishmaniasis.
6/2009	Pentavalent antimonials: new perspectives for old drugs.
7/2008	Reduced tissue parasitic load and infectivity to sand flies in dogs naturally infected by Leishmania (Leishmania) chagasi following treatment with a liposome formulation of meglumine antimoniate.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Cynthia Demicheli Research Topics

Disease

8	Visceral Leishmaniasis (Kala Azar) 01/2018 - 06/2006
6	Leishmaniasis 06/2021 - 01/2004
6	Body Weight (Weight, Body) 01/2020 - 01/2004
5	Infections 01/2020 - 04/2006
4	Cutaneous Leishmaniasis 06/2021 - 01/2004
2	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 02/2016 - 12/2011
2	Cardiotoxicity 12/2015 - 01/2014
1	Melanoma (Melanoma, Malignant) 02/2016
1	Parasitic Diseases (Parasitic Disease) 06/2009
1	Sialorrhea 07/2008
1	Tachypnea 07/2008
1	Schistosomiasis mansoni 04/2003

Drug/Important Bio-Agent (IBA)

14	Meglumine AntimoniateIBA 06/2021 - 01/2004
6	Liposomes (Liposome)IBA 01/2020 - 04/2003
6	AntimonyIBA 10/2019 - 01/2004
5	Pharmaceutical PreparationsIBA 06/2021 - 01/2008
2	Allopurinol (Remid)FDA LinkGeneric 01/2020 - 06/2012
2	betadex (beta-cyclodextrin)IBA 01/2008 - 01/2004
1	Aligeron (AS 2)IBA 01/2020
1	liposomal amphotericin B FDA Link 10/2019
1	miltefosine (Impavido)IBA 10/2019
1	LigandsIBA 02/2016
1	Coordination ComplexesIBA 02/2016
1	MART-1 AntigenIBA 02/2016
1	Antineoplastic Agents (Antineoplastics)IBA 02/2016
1	Phosphates (Orthophosphate)IBA 12/2015
1	Ascorbic Acid (Vitamin C)FDA LinkGeneric 01/2014
1	AntioxidantsIBA 01/2014
1	CarbonIBA 09/2013
1	lapacholIBA 12/2011
1	CyclodextrinsIBA 06/2009
1	Antimony Sodium Gluconate (Sodium, Stibogluconate)IBA 06/2009
1	GuanineIBA 10/2006
1	RibonucleosidesIBA 10/2006
1	Adenine FDA LinkGeneric 10/2006
1	hydroxide ionIBA 04/2006
1	Antimony Potassium TartrateIBA 04/2003

Therapy/Procedure

3	Therapeutics 10/2019 - 06/2009
1	Complementary Therapies (Alternative Medicine) 06/2021
1	Oral Administration 01/2018
1	Drug Therapy (Chemotherapy) 01/2014
1	Injections 07/2008
1	Aftercare (After-Treatment) 07/2008